Company Profiles

Print


Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, the Company's R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs in development.
Our Company's success is powered by our more than 16,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.



Alimera Sciences, founded in June 2003, and proudly established in Europe since 2013, is a pharmaceutical company that specialises in the research, development and commercialisation of prescription ophthalmic pharmaceuticals. We are presently focused on diseases of the retina, affecting millions of people in our aging populations. Our commitment to retina specialists and their patients is manifest in our product and development portfolio designed to treat early- and late-stage diseases such as DMO, AMD and RVO. Alimera's focus is to:
• Continue development of our current product portfolio in pursuit of other potential ophthalmic indications.
• Pursue the development, license or acquisition of rights to potential ophthalmic drug delivery technologies and compounds.
• Operate as an ethically driven company, recognising our responsibility to others and the importance of having a positive impact on those with whom we interact.




Bayer is a global enterprise with core competencies in the Life Science fields of healthcare and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2015, the Group employed around 117,000 people and had sales of EUR 46.3 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015.


Centervue is an Italian Company, leader in the eye care diagnostic field, that develops systems for the early detection of sight-threatening pathologies, such as Diabetic Retinopathy, Macular Degeneration and Glaucoma. Centervue innovative products are technologically advanced and highly automated. Our goal is to offer user friendly devices that allow Eye Practitioners to preserve patients’ sight and quality of vision, in particular by detecting preventable diseases.


Heidelberg Engineering is a high-tech imaging solutions company which designs, manufactures, and distributes diagnostic instruments for eye care professionals. Its products are used to scan patients' eyes for signs of disease and to assist in the management of patients found to have disease. Early recognition of disease helps to delay and prevent the most common causes of blindness.Typical diseases which can be recognized and tracked with Heidelberg Engineering's technology include glaucoma, AMD, diabetic retinopathy, and macular edema.The company's core technologies include confocal microscopy, scanning lasers and optics, optical coherence tomography, software image analysis and related IT solutions.


Lumenis is a global leader in the field of minimally-invasive clinical solutions for the Ophthalmology, Surgical and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies. In Ophthalmology, Lumenis revolutionized the way eye surgery is performed, introducing the very first ophthalmic Argon photocoagulator; the first approved Nd:YAG photodisruptor laser; developed and introduced the breakthrough technology of multicolor photocoagulation along with the world's first Laser Indirect Ophthalmoscope (LIO).
Lumenis is also the force behind the groundbreaking Selective Laser Trabeculoplasty (SLT) for managing open-angle glaucoma, offering proven clinical efficacy.
With cost-effective modular platforms, we provide physicians with maximum performance lasers and maximum patient comfort.


Optos' patented ultra-widefield digital scanning laser technology acquires images that support the detection, diagnosis, analysis, documentation and management of ocular pathology and systemic disease that may first present in the periphery. These conditions may otherwise go undetected using traditional examination techniques and equipment. Simultaneous, non-contact, central pole-to-periphery views of up to 82% or 200 degrees of the retina are displayed in one single capture, compared to 45 degrees achieved with conventional methods. Optos offers desktop devices offering multiple wavelength imaging, including options for colour, red-free, autofluorescence and angiography together with feature-rich image viewing software to view the images from Optos devices.


Optovue, a pioneer in spectral domain optical coherence tomography (SD-OCT) is a privately-held medical company based in Fremont, CA. Since introducing OCT technology to the ophthalmology market in 2006, Optovue continues to advance the technology, and has more than 11,000 systems installed worldwide. In 2014, the AngioVue Imaging System was introduced (to markets outside of the U.S.) as the world's first OCTA system capable of visualizing ocular blood flow, which provides physicians with the ability to more closely manage debilitating diseases that lead to blindness such as diabetic retinopathy and acute macular degeneration.




Topcon Corporation was founded in 1932. The former name of the company was Tokio optical Co, Ltd and it has developed its activity focusing in the innovation of ophthalmological and optometric products, being pioneer in the application of digital technology for both fields.The most important task consists in offering leading products to its customers. The second one is the globality of the company in all the manufacturing process to the distribution of the products all around the world through its daughter companies, to control all the processes and guarantee an excellent quality service to the customers.The marketing activity of the company "TIME TO MARKET", is centered in being the first one to release the most innovative products to the market. This requires an internal efficient organization, for sharing information and taking quick decisions.Topcon's goal consists in increasing its business based on its own technology, in the global development strategies and sales, all together based on the confidence of its customers.


Wisepress.com, Europe’s leading conference bookseller, attend around 200 conferences every year. We have an extensive range of books and journals relevant to the themes of this conference available at our booth. We also have a comprehensive range of STM titles available on our online bookshop. Follow us on Twitter @WisepressBooks.